Fibroblast News and Research

RSS

Fibroblasts are connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules.

Medulloblastomas that arise from different cell types might require personalized treatments

Cancers arise when a normal cell acquires a mutation in a gene that regulates cellular growth or survival. But the particular cell this mutation happens in-the cell of origin-can have an enormous impact on the behavior of the tumor, and on the strategies used to treat it.

14 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

Scientists identify biomarker associated with tamoxifen resistance in women with breast cancer

Scientists have identified a molecular 'flag' in women with breast cancer who do not respond or have become resistant to the hormone drug tamoxifen.

From The University of Manchester 3 Nov 2012

Stem cell study may help to unravel how genetic mutation leads to Parkinson's symptoms

By reprogramming skin cells from Parkinson's disease patients with a known genetic mutation, researchers at the Salk Institute for Biological Studies have identified damage to neural stem cells as a powerful player in the disease.

20 Oct 2012

FGF21 hormone markedly increases life span in mice

A study by UT Southwestern Medical Center researchers finds that a starvation hormone markedly extends life span in mice without the need for calorie restriction.

17 Oct 2012

Conditionally reprogrammed cells help identify effective therapy for HPV-positive RRP

Using a newly discovered cell technology, Georgetown University Medical Center researchers were able to identify an effective therapy for a patient with a rare type of lung tumor. The single case study, reported in the September 27 issue of New England Journal of Medicine, provides a snapshot of the new technology's promising potential; however, researchers strongly caution that it could be years before validation studies are completed and regulatory approval received for its broader use.

28 Sep 2012

Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

Boehringer Ingelheim Pharmaceuticals, Inc. announced that clinical trial enrollment has completed for two phase III studies evaluating the safety and efficacy of nintedanib (BIBF 1120), an investigational compound, in patients with idiopathic pulmonary fibrosis (IPF), being studied at a twice-daily oral dose.

27 Sep 2012

Boehringer Ingelheim completes enrollment in nintedanib Phase III trials for IPF

Boehringer Ingelheim is pleased to announce the last patients have been randomised into the Phase III sister trials assessing the efficacy and safety of nintedanib (150 mg twice daily) in patients with idiopathic pulmonary fibrosis (IPF).

24 Sep 2012

Autologous skin grafts heal chronic foot ulcers

Scientists have successfully treated chronic diabetic foot ulcers using skin grafts grown from individual patient cell samples.

13 Sep 2012

Converting blood cells to a stem cell state: an interview with Elias Zambidis, M.D., Ph.D.

The primitive stem cell state we created is called an “induced pluripotent stem cell” (iPSC). iPSC are a new, unique, and artificially-created type of stem cell that were first described in 2006 by a Japanese scientist named Shinya Yamanaka.

4 Sep 2012

Morphological changes occur rapidly in response to cardiac injury

Cardiac injury leads to significant structural changes in the heart, including enlargement, excess formation of fibrous growth tissue, and abnormalities of the coronary vasculature. While associated factors have been targeted for therapeutic intervention, the results have been conflicting. Most studies have investigated these changes after six days of injury. However, advanced stages of remodeling have already begun by day seven following injury.

4 Sep 2012

Morphotek commences MORAb-004 Phase II metastatic soft tissue sarcoma trial

Morphotek, Inc. announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004 when combined with gemcitabine and docetaxel in the treatment of metastatic soft tissue sarcoma.

28 Aug 2012

Study uncovers new pathway that can treat depression

Depression takes a substantial toll on brain health. Brain imaging and post-mortem studies provide evidence that the wealth of connections in the brain are reduced in individuals with depression, with the result of impaired functional connections between key brain centers involved in mood regulation. Glial cells are one of the cell types that appear to be particularly reduced when analyzing post-mortem brain tissue from people who had depression.

16 Aug 2012

Glioblastoma patients with modified PTEN have resistance to EGFR inhibitors

Despite years of research, glioblastoma, the most common and deadly brain cancer in adults, continues to outsmart treatments targeted to inhibit tumor growth.

15 Aug 2012

Interface zone fibroblasts play key role in gastric cancer

Interface zone fibroblasts in gastric adenocarcinoma promote the invasion, migration, and proliferation of cancer cells, as well as prevent apoptosis, to a greater degree than normal or tumor zone fibroblasts, say researchers.

8 Aug 2012

Scientists identify key factor that drives resistance to cancer drug

Developing resistance to chemotherapy is a nearly universal, ultimately lethal consequence for cancer patients with solid tumors - such as those of the breast, prostate, lung and colon - that have metastasized, or spread, throughout the body. A team of scientists led by Fred Hutchinson Cancer Research Center has discovered a key factor that drives this drug resistance - information that ultimately may be used to improve the effectiveness of therapy and buy precious time for patients with advanced cancer.

6 Aug 2012

Fibroblast News and Research

Further Reading

Medulloblastomas that arise from different cell types might require personalized treatments

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Scientists identify biomarker associated with tamoxifen resistance in women with breast cancer

Stem cell study may help to unravel how genetic mutation leads to Parkinson's symptoms

FGF21 hormone markedly increases life span in mice

Conditionally reprogrammed cells help identify effective therapy for HPV-positive RRP

Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

Boehringer Ingelheim completes enrollment in nintedanib Phase III trials for IPF

Autologous skin grafts heal chronic foot ulcers

Converting blood cells to a stem cell state: an interview with Elias Zambidis, M.D., Ph.D.

Morphological changes occur rapidly in response to cardiac injury

Morphotek commences MORAb-004 Phase II metastatic soft tissue sarcoma trial

Study uncovers new pathway that can treat depression

Glioblastoma patients with modified PTEN have resistance to EGFR inhibitors

Interface zone fibroblasts play key role in gastric cancer

Scientists identify key factor that drives resistance to cancer drug

Skin cell spray key to venous leg ulcer treatment

Scientists discover critical molecular switch that regulates autophagy

Burn wound MSCs potential source for skin grafting

Fusion of FGFR and TACC gene leads to glioblastoma

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News